7 April, 2016
AAT Research today announced that it has appointed pharmaceutical and medical industry veteran Wolfgang Storf as its new chief executive officer.
Mr Storf brings more than 20 years of experience in the industry with a successful record of entering new markets, providing strategic direction and boosting growth.
Prior to joining AAT, he was chief strategy officer with the MS Pharma Group. He was also CEO of Novartis-Sandoz in South Africa and held other senior management positions with Novartis-Sandoz, Apotex and Johnson & Johnson in different regions of the world. Mr Storf is a seasoned senior executive with proven global strategic and execution leadership experience – covering both commercial and technical operations as well R&D responsibility inside multinational and private businesses in the pharmaceutical and medical industry. He also has experience in post-merger integration programs in both branded / un-branded markets.
“I am delighted to take over as CEO at this important stage of AAT’s growth, and I’m looking forward to working with the executive team and the board to help the company realise its full potential, enter new markets and establish our products as leading therapies and services for patients and medical professionals respectively,” Mr Storf said.
AAT Research’s Founder and Chief Scientific Officer, Dr Adrian Attard Trevsisan, said: “We have come a long way from a small one-room setup. As the company continues to grow and increase its international footprint, we felt the need to bring in a senior executive who has extensive international experience in the pharmaceutical and medical industries.”
“The board of directors and I are extremely pleased that Wolfgang has joined the company and he will be a determining factor in the internationalisation of AAT in the coming months. I will be taking on the role of Chief Scientific Officer and Director of Product, focusing on research, innovation and product development,” Dr Attard Trevisan added.